|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: SLC1A7 |
Gene summary for SLC1A7 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | SLC1A7 | Gene ID | 6512 |
| Gene name | solute carrier family 1 member 7 | |
| Gene Alias | AAAT | |
| Cytomap | 1p32.3 | |
| Gene Type | protein-coding | GO ID | GO:0001504 | UniProtAcc | A0A087WUF9 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 6512 | SLC1A7 | HCC1_Meng | Human | Liver | HCC | 7.89e-17 | 8.07e-02 | 0.0246 |
| 6512 | SLC1A7 | S014 | Human | Liver | HCC | 1.71e-23 | 1.16e+00 | 0.2254 |
| 6512 | SLC1A7 | S015 | Human | Liver | HCC | 5.26e-33 | 1.90e+00 | 0.2375 |
| 6512 | SLC1A7 | S016 | Human | Liver | HCC | 9.70e-41 | 1.35e+00 | 0.2243 |
| 6512 | SLC1A7 | S027 | Human | Liver | HCC | 3.60e-07 | 5.08e-01 | 0.2446 |
| 6512 | SLC1A7 | S028 | Human | Liver | HCC | 2.20e-11 | 5.23e-01 | 0.2503 |
| 6512 | SLC1A7 | S029 | Human | Liver | HCC | 5.39e-28 | 1.05e+00 | 0.2581 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| SLC1A7 | SNV | Missense_Mutation | c.281C>T | p.Ala94Val | p.A94V | protein_coding | tolerated(1) | benign(0.039) | TCGA-A1-A0SH-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | tc | SD | ||
| SLC1A7 | SNV | Missense_Mutation | rs778796774 | c.1657G>A | p.Glu553Lys | p.E553K | protein_coding | tolerated(0.12) | benign(0.378) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| SLC1A7 | SNV | Missense_Mutation | rs201010691 | c.85N>A | p.Val29Met | p.V29M | protein_coding | deleterious(0.04) | possibly_damaging(0.694) | TCGA-AR-A0TZ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unspecific | Doxorubicin | PD | |
| SLC1A7 | SNV | Missense_Mutation | c.11A>G | p.His4Arg | p.H4R | protein_coding | tolerated(0.53) | benign(0) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| SLC1A7 | SNV | Missense_Mutation | c.1254N>G | p.Asn418Lys | p.N418K | protein_coding | tolerated(0.12) | possibly_damaging(0.747) | TCGA-C8-A27B-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR | ||
| SLC1A7 | SNV | Missense_Mutation | rs201010691 | c.85N>A | p.Val29Met | p.V29M | protein_coding | deleterious(0.04) | possibly_damaging(0.694) | TCGA-LQ-A4E4-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | anastrozole | PD | |
| SLC1A7 | SNV | Missense_Mutation | c.524N>T | p.Glu175Val | p.E175V | protein_coding | tolerated(0.22) | benign(0.009) | TCGA-S3-AA10-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cytoxan | CR | ||
| SLC1A7 | insertion | Frame_Shift_Ins | novel | c.1098_1099insATTAAGTC | p.His367IlefsTer156 | p.H367Ifs*156 | protein_coding | TCGA-AO-A0J5-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Other, specify in notesBisphosphonate | zoledronic | PD | |||
| SLC1A7 | insertion | Frame_Shift_Ins | novel | c.1096_1097insTGGACCCTGT | p.Arg366MetfsTer18 | p.R366Mfs*18 | protein_coding | TCGA-AO-A0J5-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Other, specify in notesBisphosphonate | zoledronic | PD | |||
| SLC1A7 | SNV | Missense_Mutation | novel | c.893T>G | p.Val298Gly | p.V298G | protein_coding | deleterious(0) | benign(0.268) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 6512 | SLC1A7 | TRANSPORTER, DRUGGABLE GENOME | 178101255 | |||
| 6512 | SLC1A7 | TRANSPORTER, DRUGGABLE GENOME | inhibitor | 178101349 | ||
| 6512 | SLC1A7 | TRANSPORTER, DRUGGABLE GENOME | 178101410 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |